This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care. 2001 Jul;24(7):1221-5. [4]Shukla AP， Dickison M， ...

nateglinide + rosiglitazone; , placebo and rosiglitazone. Plasma glucose (A) and immunoreactive insulin (IRI) (B) during standardized meal challenges performed at week 0 and after 24 weeks of ...

However, its acute glucose lowering effect is comparable to other diabetic medications like Acarbose and Nateglinide. This doesn’t mean people should stop taking medications and do food order ...

The goal of this study was to assess the safety, tolerability, and metabolic effects of nateglinide in a prediabetic population and to thereby establish the feasibility of using nateglinide for a ...

Type 2 diabetes is a form of diabetes characterized by high blood sugar (glucose), insulin resistance, and a decrease in insulin production. For some people, type 2 diabetes can be managed with ...